Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Regen BioPharma Inc from 30 Sep 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Regen BioPharma Inc quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 30 Sep 2023 to 31 Dec 2025.
  • Regen BioPharma Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 31 Dec 2025 was $967,853, a 88% decline year-over-year.
  • Regen BioPharma Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 31 Dec 2025 was $1,726,971, a 66% decline year-over-year.
  • Regen BioPharma Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $1,274,502, a 91% decline from 2024.
  • Regen BioPharma Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $668,255, a 158% decline from 2023.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Regen BioPharma Inc Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,726,971 $967,853 -$452,469 -88% 01 Oct 2025 31 Dec 2025 10-Q 13 Feb 2026 2026 Q1
Q3 2025 $1,274,502 $572,472 -$301,723 -111% 01 Jul 2025 30 Sep 2025 10-K 30 Dec 2025 2025 FY
Q2 2025 $972,779 $167,292 -$37,172 -29% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q3
Q1 2025 $935,607 $19,354 +$103,100 +84% 01 Jan 2025 31 Mar 2025 10-Q 28 May 2025 2025 Q2
Q4 2024 $1,038,707 $515,384 -$370,452 -256% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2026 2026 Q1
Q3 2024 $668,255 $270,749 01 Jul 2024 30 Sep 2024 10-K 30 Dec 2025 2025 FY
Q2 2024 $130,120 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q3
Q1 2024 $122,454 01 Jan 2024 31 Mar 2024 10-Q 28 May 2025 2025 Q2
Q4 2023 $144,932 01 Oct 2023 31 Dec 2023 10-Q 16 May 2025 2025 Q1

Regen BioPharma Inc Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $1,274,502 -$606,247 -91% 01 Oct 2024 30 Sep 2025 10-K 30 Dec 2025 2025 FY
2024 $668,255 -$1,824,762 -158% 01 Oct 2023 30 Sep 2024 10-K 30 Dec 2025 2025 FY
2023 $1,156,507 01 Oct 2022 30 Sep 2023 10-K 13 May 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.